Abstract
We evaluated the gain in long-term survival of BDIX rats bearing DHDProB colon cancer developed in the peritoneal cavity after in vivo therapy with the tk gene and GCV. The sensitivity and the bystander effect of DHDProB cells stably transduced with the tk gene evaluated in vitro were low, as one tk+ cell killed two tk− cells. This correlated with the low ability of a fluorescent dye to diffuse through gap junctions. In vivo, more than 75% of tk-transduced cells were required and at least 100 mg/kg/day of GCV had to be injected no later than day 5 after tumor implantation to obtain a curative effect. A partial protection of the cured animals against rechallenge with the parental cells was also observed. Based on these results, a protocol of in vivo gene therapy was designed in which the tk/GCV treatment was combined with IL-2 gene expression. When the tk- and IL-2 encoding plasmids were injected twice i.p. with DOTAP and the animals treated with GCV, three of five rats were cured. This antitumoral activity resulted from the combined toxic effects of DNA/DOTAP and tk/GCV plus a potential immune response mediated by IL-2.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$259.00 per year
only $21.58 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Coll, JL., Mesnil, M., Lefebvre, MF. et al. Long-term survival of immunocompetent rats with intraperitoneal colon carcinoma tumors using herpes simplex thymidine kinase/ganciclovir and IL-2 treatments. Gene Ther 4, 1160–1166 (1997). https://doi.org/10.1038/sj.gt.3300516
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1038/sj.gt.3300516
Keywords
This article is cited by
-
A novel bystander effect involving tumor cell-derived Fas and FasL interactions following Ad.HSV-tk and Ad.mIL-12 gene therapies in experimental prostate cancer
Gene Therapy (2002)
-
Delivery Systems for Pulmonary Gene Therapy
American Journal of Respiratory Medicine (2002)
-
Recombinant adenoviral vectors have adjuvant activity and stimulate T cell responses against tumor cells
Gene Therapy (2000)